Literature DB >> 25609807

Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.

Julie Delaloye1, Abdelali Filali-Mouhim2, Mark J Cameron2, Elias K Haddad2, Alexandre Harari3, Jean-Pierre Goulet2, Carmen E Gomez4, Beatriz Perdiguero4, Mariano Esteban4, Giuseppe Pantaleo3, Thierry Roger1, Rafick-Pierre Sékaly2, Thierry Calandra5.   

Abstract

UNLABELLED: NYVAC, a highly attenuated, replication-restricted poxvirus, is a safe and immunogenic vaccine vector. Deletion of immune evasion genes from the poxvirus genome is an attractive strategy for improving the immunogenic properties of poxviruses. Using systems biology approaches, we describe herein the enhanced immunological profile of NYVAC vectors expressing the HIV-1 clade C env, gag, pol, and nef genes (NYVAC-C) with single or double deletions of genes encoding type I (ΔB19R) or type II (ΔB8R) interferon (IFN)-binding proteins. Transcriptomic analyses of human monocytes infected with NYVAC-C, NYVAC-C with the B19R deletion (NYVAC-C-ΔB19R), or NYVAC-C with B8R and B19R deletions (NYVAC-C-ΔB8RB19R) revealed a concerted upregulation of innate immune pathways (IFN-stimulated genes [ISGs]) of increasing magnitude with NYVAC-C-ΔB19R and NYVAC-C-ΔB8RB19R than with NYVAC-C. Deletion of B8R and B19R resulted in an enhanced activation of IRF3, IRF7, and STAT1 and the robust production of type I IFNs and of ISGs, whose expression was inhibited by anti-type I IFN antibodies. Interestingly, NYVAC-C-ΔB8RB19R induced the production of much higher levels of proinflammatory cytokines (tumor necrosis factor [TNF], interleukin-6 [IL-6], and IL-8) than NYVAC-C or NYVAC-C-ΔB19R as well as a strong inflammasome response (caspase-1 and IL-1β) in infected monocytes. Top network analyses showed that this broad response mediated by the deletion of B8R and B19R was organized around two upregulated gene expression nodes (TNF and IRF7). Consistent with these findings, monocytes infected with NYVAC-C-ΔB8RB19R induced a stronger type I IFN-dependent and IL-1-dependent allogeneic CD4(+) T cell response than monocytes infected with NYVAC-C or NYVAC-C-ΔB19R. Dual deletion of type I and type II IFN immune evasion genes in NYVAC markedly enhanced its immunogenic properties via its induction of the increased expression of type I IFNs and IL-1β and make it an attractive candidate HIV vaccine vector. IMPORTANCE: NYVAC is a replication-deficient poxvirus developed as a vaccine vector against HIV. NYVAC expresses several genes known to impair the host immune defenses by interfering with innate immune receptors, cytokines, or interferons. Given the crucial role played by interferons against viruses, we postulated that targeting the type I and type II decoy receptors used by poxvirus to subvert the host innate immune response would be an attractive approach to improve the immunogenicity of NYVAC vectors. Using systems biology approaches, we report that deletion of type I and type II IFN immune evasion genes in NYVAC poxvirus resulted in the robust expression of type I IFNs and interferon-stimulated genes (ISGs), a strong activation of the inflammasome, and upregulated expression of IL-1β and proinflammatory cytokines. Dual deletion of type I and type II IFN immune evasion genes in NYVAC poxvirus improves its immunogenic profile and makes it an attractive candidate HIV vaccine vector.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25609807      PMCID: PMC4403427          DOI: 10.1128/JVI.03061-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

Review 1.  Poxvirus vectors as HIV/AIDS vaccines in humans.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Juan Garcia-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

2.  Regulation of interleukin-1beta by interferon-gamma is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production.

Authors:  Seth L Masters; Lisa A Mielke; Ann L Cornish; Caroline E Sutton; Joanne O'Donnell; Louise H Cengia; Andrew W Roberts; Ian P Wicks; Kingston H G Mills; Ben A Croker
Journal:  EMBO Rep       Date:  2010-07-02       Impact factor: 8.807

Review 3.  Central roles of NLRs and inflammasomes in viral infection.

Authors:  Thirumala-Devi Kanneganti
Journal:  Nat Rev Immunol       Date:  2010-09-17       Impact factor: 53.106

Review 4.  Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.

Authors:  Mariano Esteban
Journal:  Hum Vaccin       Date:  2009-12-03

5.  The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses.

Authors:  Vijay A K Rathinam; Zhaozhao Jiang; Stephen N Waggoner; Shruti Sharma; Leah E Cole; Lisa Waggoner; Sivapriya Kailasan Vanaja; Brian G Monks; Sandhya Ganesan; Eicke Latz; Veit Hornung; Stefanie N Vogel; Eva Szomolanyi-Tsuda; Katherine A Fitzgerald
Journal:  Nat Immunol       Date:  2010-03-28       Impact factor: 25.606

6.  Dissecting interferon-induced transcriptional programs in human peripheral blood cells.

Authors:  Simon J Waddell; Stephen J Popper; Kathleen H Rubins; Michael J Griffiths; Patrick O Brown; Michael Levin; David A Relman
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

7.  Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression.

Authors:  Franz G Bauernfeind; Gabor Horvath; Andrea Stutz; Emad S Alnemri; Kelly MacDonald; David Speert; Teresa Fernandes-Alnemri; Jianghong Wu; Brian G Monks; Katherine A Fitzgerald; Veit Hornung; Eicke Latz
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

8.  Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas.

Authors:  Cheolho Cheong; Ines Matos; Jae-Hoon Choi; Durga Bhavani Dandamudi; Elina Shrestha; M Paula Longhi; Kate L Jeffrey; Robert M Anthony; Courtney Kluger; Godwin Nchinda; Hyein Koh; Anthony Rodriguez; Juliana Idoyaga; Maggi Pack; Klara Velinzon; Chae Gyu Park; Ralph M Steinman
Journal:  Cell       Date:  2010-10-29       Impact factor: 41.582

9.  Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production.

Authors:  Hendrik Poeck; Michael Bscheider; Olaf Gross; Katrin Finger; Susanne Roth; Manuele Rebsamen; Nicole Hannesschläger; Martin Schlee; Simon Rothenfusser; Winfried Barchet; Hiroki Kato; Shizuo Akira; Satoshi Inoue; Stefan Endres; Christian Peschel; Gunther Hartmann; Veit Hornung; Jürgen Ruland
Journal:  Nat Immunol       Date:  2009-11-15       Impact factor: 25.606

10.  Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors.

Authors:  Esther D Quakkelaar; Anke Redeker; Elias K Haddad; Alexandre Harari; Stella Mayo McCaughey; Thomas Duhen; Abdelali Filali-Mouhim; Jean-Philippe Goulet; Nikki M Loof; Ferry Ossendorp; Beatriz Perdiguero; Paul Heinen; Carmen E Gomez; Karen V Kibler; David M Koelle; Rafick P Sékaly; Federica Sallusto; Antonio Lanzavecchia; Giuseppe Pantaleo; Mariano Esteban; Jim Tartaglia; Bertram L Jacobs; Cornelis J M Melief
Journal:  PLoS One       Date:  2011-02-15       Impact factor: 3.240

View more
  6 in total

1.  HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.

Authors:  Juan García-Arriaza; Beatriz Perdiguero; Jonathan L Heeney; Michael S Seaman; David C Montefiori; Nicole L Yates; Georgia D Tomaras; Guido Ferrari; Kathryn E Foulds; Mario Roederer; Steven G Self; Bhavesh Borate; Raphael Gottardo; Sanjay Phogat; Jim Tartaglia; Susan W Barnett; Brian Burke; Anthony D Cristillo; Deborah E Weiss; Carter Lee; Karen V Kibler; Bertram L Jacobs; Ralf Wagner; Song Ding; Giuseppe Pantaleo; Mariano Esteban
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

2.  The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination.

Authors:  Jeffrey Alan Tomalka; Adam Nicolas Pelletier; Slim Fourati; Muhammad Bilal Latif; Ashish Sharma; Kathryn Furr; Kevin Carlson; Michelle Lifton; Ana Gonzalez; Peter Wilkinson; Genoveffa Franchini; Robert Parks; Norman Letvin; Nicole Yates; Kelly Seaton; Georgia Tomaras; Jim Tartaglia; Merlin L Robb; Nelson L Michael; Richard Koup; Barton Haynes; Sampa Santra; Rafick Pierre Sekaly
Journal:  Nat Immunol       Date:  2021-09-23       Impact factor: 31.250

Review 3.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

4.  RNA-Seq Based Transcriptome Analysis of the Type I Interferon Host Response upon Vaccinia Virus Infection of Mouse Cells.

Authors:  Bruno Hernáez; Graciela Alonso; Juan Manuel Alonso-Lobo; Alberto Rastrojo; Cornelius Fischer; Sascha Sauer; Begoña Aguado; Antonio Alcamí
Journal:  J Immunol Res       Date:  2017-02-09       Impact factor: 4.818

5.  Blockade of beta adrenergic receptors protects the blood brain barrier and reduces systemic pathology caused by HIV-1 Nef protein.

Authors:  Jocelyn Rivera-Ortiz; Jessalyn Pla-Tenorio; Myrella L Cruz; Krystal Colon; Jaileene Perez-Morales; Julio A Rodriguez; Jorge Martinez-Sicari; Richard J Noel
Journal:  PLoS One       Date:  2021-11-16       Impact factor: 3.752

6.  Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses.

Authors:  María Pía Holgado; Juliana Falivene; Cynthia Maeto; Micaela Amigo; María Fernanda Pascutti; María Belén Vecchione; Andrea Bruttomesso; Gabriela Calamante; María Paula Del Médico-Zajac; María Magdalena Gherardi
Journal:  Viruses       Date:  2016-05-23       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.